Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Affibody and Inmagene autoimmune partnership completes regulatory milestone Affibody and Inmagene Biopharmaceuticals report that the US FDA has cleared the interleukin-17 (IL-17) blocker, izokibep, to proceed to phase 2 clinical development in non-infectious intermediate, posterior, and pan-uveitis.
Uveitis is an orphan disease with significant unmet medical need. It is an inflammation of the uveal tract but can also include the inflammation of nearby tissues, such as the retina, the optic nerve, and the vitreous humor. It is one of the leading causes of blindness worldwide.
Sweden’s Affibody and Inmagene, which has wholly owned subsidiaries in San Diego, Shanghai, and Hangzhou, are jointly developing izokibep, a novel bispecific agent, targeting both subunits of IL-17A as well as albumin, to treat multiple autoimmune diseases.
The Fifth Annual Retina Fellow Summit
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME
Activity Expiration Date: 12/31/2021
Activity Overview
This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transitions.
The overall goal of this program is to provide retina fellows, ophthalmology residents, retina specialists, and comprehensive ophthalmologists who treat diseases of the retina with cutting-edge clinical data, translational research, and practice information to optimize patient care and facilitate practice transitions.